In the rush to assess the role of stem cell therapy for cardiovascular disease the details of translation are easily overlooked. This review summarises the progress to date in translating the exciting preclinical results of cardiac repair into man and considers the questions that this area of research has stimulated about the challenges of moving from bench to bedside.
- Stem cell
- regenerative medicine
- clinical trials
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
This is a reprint of a paper that first appeared in Heart, October 2010, Volume 96, pages 1531–1537.
Funding This work forms part of the research themes contributing to the translational research portfolio of Barts and the London Cardiovascular Biomedical Research Unit, which is supported and funded by the National Institute of Health Research. Dr Matthew Lovell was funded by the British Heart Foundation during work included in this manuscript. Professor Mathur's clinical research in this area is funded by the Heart Cells Foundation, UK Stem Cell Foundation and Barts and the London Charity.
Competing interests None.
Provenance and peer review Commissioned; externally peer reviewed.